Rol' infliksimaba v lechenii ankiloziruyushchego spondilita


Cite item

Full Text

Abstract

Контролируемые исследования при анкилозирующем спондилите (АС) сульфасалазина, метотрексата, а по предварительным данным и лефлуномида не выявили безусловного превосходства над плацебо при аксиальной форме заболевания. Эти препараты недостаточно “надежны” и в случае поражения при АС периферических суставов [1, 2]. У большинства больных АС основную роль в лечении продолжают играть (наряду с физическими упражнениями, физиотерапией и образованием пациентов) нестероидные противовоспалительные препараты (НПВП). Поэтому появление первых сообщений об эффективности нового класса препаратов, ингибиторов фактора некроза опухолей-a (ФНО-a) при ревматоидном артрите было встречено с большим воодушевлением, и вскоре эти "биологические" препараты стали испытываться и у больных АС. В данном обзоре приводятся сведения только об одном из этих препаратов – инфликсимабе.

About the authors

A. G Bochkova

ГУ Институт ревматологии РАМН, Москва

Лаборатория серонегативных спондилоартритов и остеоартроза

References

  1. Chen J, Lui C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2004; 3: CD004524.
  2. Chen J, Lui C. Sulfasalasin for ankylosing spondylitis. Cochrane Database Syst Rev 2005, Apr 18; 2: CD004800.
  3. van den Bosch F, Kruithof E, Baeten D et al. Effects of loading dose regimen of three infusions of chimeric antibody to tumor necrosis factor (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428–33.
  4. Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the antitumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346–52.
  5. van der Bosch F, Kruthof E, Baeten D et al. Safety and efficacy of a retreatment regimen of 10mg/kg infliximab every 14 weeks in patients with active spondyloarthropathy. Arthritis Rheum 2002; 46 (9 Suppl): S430.
  6. Breban M, Vignon E, Claudepierre P et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six - month open - label study. Rheumatology (Oxford) 2002; 41: 1280–5.
  7. Temekonidis T.I, Alamanos Y, Nikas S.N et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62 (12): 1218–20.
  8. Maksymowych W, Jhangri G, Lambert R et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29: 959–65.
  9. Braun J, Brandt J, Listing J et al. Long - term efficacy and safety of infliximab in the treatment of ankylosing spondilitis: an open, observational, extension study of a three - month, randomized, placebo - controlled trial. Arthritis Rheum 2003; 48: 2224–33.
  10. Braun J, Brandt J, Listing J et al. Two year maintenance of efficacy and safety on infliximab in the treatment of ankylosing spondilitis. Ann Rheum Dis 2005; 64: 229–34.
  11. Baraliakos X, Brandt J, Listing J et al. Clinical response to long - term therapy with infliximab in patients with ankylosing spondylitis - results after 3 years [abstract]. Presented at: Annual European Congress of Rheumatology; Berlin Germany; June 9–12, 2004. Abstract SAT0084.
  12. van der Bosch F, Kruthof E, Baeten D et al. Randomized double - blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloartghropathy. Arthritis Rheum 2002; 46: 755–65.
  13. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondilitis. Results of a randomized, placebo controlled trial (ASSERT). Arthritis Rhum 2005; 52: 582–91.
  14. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187–93.
  15. Marzo-Ortega H, Mc Gonagle D, Jarrett S et al. Infliximab in combination with methotrexate in active ankylosing spondylitis. A clinical and imaging study. Ann Rheum Dis 2005 May 26; [Epub ahead of print].
  16. Lipsky P.E, van der Heijde, St. Clair E.W et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602.
  17. Rudwaleit M, Listing J, Brandt J et al. Prediction on a major clinical response (BASDAI 50) to TNF-ablokers in ankylosing spondilitis? Ann Rheum Dis 2004; 63: 665–70.
  18. Rudwaleit M, Siegert S, Yin Z et al. Low T cell production of TNF-a and INF-g in ankylosing spondylitis its relation to HLA-B27 and influense of the TNF-308 gene polymorphism. Ann Rheum Dis 2001; 60: 36–42.
  19. Gonsales S, Torre-Alonso J.C, Martines-Borra J et al. TNF-238A promoter polymorphism contributes to susceptibility to ankylosing spondylitis in HLA-B27 negative patients. J Rheumatol 2001; 28: 1288–93.
  20. Braun J, Baraliakos X, Golder W et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48: 1126–36.
  21. Kruithof, D Baeten, F Van den Bosch, H Mielants, E M Veys and F De Keyser Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy Ann Rheum Dis; April 2005 (Volume 64, Number 4).
  22. Xenofon Baraliakos, Joachim Listing, Martin Rudwaleit et al. Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor-З antibody infliximab. Ann Rheum Dis Apr 2005; 64 (4).
  23. Brandt J, Listing J, Krause A et al. Socioeconomic consequences for patients with active ankylosing spondylitis treated for two years with infliximab in a clinical trial [abstract]. Ann Rheum Dis 2003; 62 (Suppl. 1). Abstract FRI0201.
  24. Румянцева О.А, Кузин А.В, Бунчук Н.В. Применение ремикейда при анкилозирующем спондилоартрите (предварительные результаты). Клин. фармакол. и тер. 2004; 13 (1): 89–93.
  25. Бунчук Н.В., Румянцева О.А, Бочкова А.Г. и др. Анкилозирующий спондилит: международный и отечественный опыт применения инфликсимаба. V Российский съезд ревматологов, Казань, май 2005 г., симпозиум "Антицитокиновая терапия при ревматических заболеваниях".
  26. Hyrich K.L, Silman A.J, Watson K.D, D.P.M Symmons. Anti - tumor necrosis factor a therapy in rheumatoid arthritis: an update on safety. Ann Rheumatic Disease 2004; 63 (12): 1538–43.
  27. Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti - tumor necrosis factor agents in patients with ankylosing spondilitis. Ann Rheum Dis 2003; 62: 817–24.
  28. Carmona L, Gomes-Reino J.J, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonist. Arthritis Rheum 2005, Jun 2; 52 (6): 1766–72.
  29. Van der Linden et al. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8.

Copyright (c) 2005 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies